- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week | 173 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, January 7, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, will present at the Biotech... ► Artikel lesen | |
| Mi | Evaxion A/S - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 19.12.25 | Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out | 4 | Benzinga.com | ||
| 19.12.25 | Merck turns down option to Evaxion's gonorrhea vaccine, prompting Danish biotech to seek other partners | 11 | FierceBiotech | ||
| 19.12.25 | MSD declines option for Evaxion's gonorrhea vaccine candidate | 10 | Investing.com | ||
| 19.12.25 | Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2 | 467 | GlobeNewswire (Europe) | MSD declines to exercise option for EVX-B2 developmentEvaxion is now able to out-license EVX-B2 to another partnerEvaxion maintains its strong belief in EVX-B2, which has shown to be protective against... ► Artikel lesen | |
| 19.12.25 | Evaxion A/S - 6-K, Report of foreign issuer | - | SEC Filings | ||
| EVAXION Aktie jetzt für 0€ handeln | |||||
| 10.12.25 | Evaxion Biotech stock holds Buy rating at H.C. Wainwright after ASH data | 1 | Investing.com | ||
| 08.12.25 | Evaxion A/S - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 06.12.25 | Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting | 547 | GlobeNewswire (Europe) | Designed with our proprietary AI-Immunology platform based on patient sequencing data, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigensEVX-04 induces targeted immune... ► Artikel lesen | |
| 21.11.25 | Evaxion A/S - F-1, Registration statement for certain foreign private issuers | - | SEC Filings | ||
| 20.11.25 | Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1 | 297 | GlobeNewswire (Europe) | Evaxion's AI-Immunology platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models EVX-V1 is a next-generation, multi-component vaccine program combining... ► Artikel lesen | |
| 20.11.25 | Evaxion A/S - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 12.11.25 | Evaxion announce 2026 financial calendar | 320 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, November 12, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, announces its financial calendar... ► Artikel lesen | |
| 12.11.25 | Evaxion A/S - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 08.11.25 | Evaxion presents new immune data for AI-designed cancer vaccine | 1 | Investing.com | ||
| 07.11.25 | Evaxion präsentiert neue Immun-Daten für KI-gestützten Krebsimpfstoff | 1 | Investing.com Deutsch | ||
| 07.11.25 | Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 | 689 | GlobeNewswire (Europe) | New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual MeetingFollowing the recent presentation of unprecedented two-year clinical efficacy data from the... ► Artikel lesen | |
| 06.11.25 | Evaxion Biotech ADS GAAP EPS of $0.01 beats by $0.02, revenue of $7.49M beats by $4.99M | 1 | Seeking Alpha | ||
| 06.11.25 | Evaxion announces business update and third quarter 2025 financial results | 273 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, November 6, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, provides business update... ► Artikel lesen |
1 2 3 4 Weiter >>
74 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 85,30 | -0,52 % | BYD gegen Tesla! KI-Profiteure BioNTech und Rio Tinto Partner Aspermont! Aktien für 2026? | Paukenschlag kurz vor Silvester! BYD hat Tesla vom E-Auto-Thron gestoßen. Die Chinesen sind jetzt auch Weltmarktführer bei rein elektrischen Fahrzeugen. Doch die Aktie hat 2025 klar enttäuscht. Ein... ► Artikel lesen | |
| EVOTEC | 6,342 | +0,83 % | EQS-News: Evotec SE: Evotec ernennt Dr. Sarah Fakih als EVP, Leiterin Global Communications und Investor Relations | EQS-News: Evotec SE
/ Schlagwort(e): Personalie
Evotec ernennt Dr. Sarah Fakih als EVP, Leiterin Global Communications und Investor Relations
01.01.2026 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| QIAGEN | 41,025 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| AMGEN | 289,15 | -1,16 % | Amgen übernimmt Dark Blue für bis zu 840 Millionen Dollar | DJ Amgen übernimmt Dark Blue für bis zu 840 Millionen Dollar
Von Colin Kellaher
DOW JONES--Amgen hat das britische Biotechnologieunternehmen Dark Blue Therapeutics für bis zu 840 Millionen... ► Artikel lesen | |
| NOVAVAX | 6,457 | -0,97 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| STRYKER | 317,00 | +0,73 % | VB Spine LLC: VB Spine Completes Acquisition of Cestas Manufacturing Facility from Stryker | Deal expands global manufacturing footprint and positions VB Spine for future growth in spine care VB Spine LLC ("VB Spine") today completed the acquisition of Stryker's spine implant manufacturing... ► Artikel lesen | |
| BIOGEN | 158,90 | -0,75 % | Mizuho hebt Kursziel für Biogen auf 207 Dollar an und verweist auf verbesserte Aussichten für 2026 | ||
| CRISPR THERAPEUTICS | 48,600 | -2,41 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112) in Autoimmune Diseases and Hematologic Malignancies | -Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the... ► Artikel lesen | |
| CORE ONE LABS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| OCUGEN | 1,281 | -6,26 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,770 | +0,29 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 14,595 | +29,16 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 41,210 | -22,07 % | Regencell Bioscience is the top performing pharma stock YTD | ||
| ENLIVEN THERAPEUTICS | 24,440 | +57,98 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| ALUMIS | 17,500 | -2,34 % | What's Going On With Alumis Stock Thursday? |
EVAXION A/S ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,56 % bei einem Aktienkurs von 5,420 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EVAXION A/S ADR finden Sie auf Wallstreet Online.